OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Aug 7, 2023 • 15min
S9 Ep16: Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCINTIX biology-guided technology; and how John Theurer Cancer Center plans to use this technology and help advance its role in the field of radiation oncology.
Aug 3, 2023 • 21min
S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.
Jul 31, 2023 • 11min
S9 Ep14: Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST
Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and research seeking to expand the targeted therapy armamentarium.
Jul 24, 2023 • 21min
S9 Ep13: Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL
Dr Lunning sits down with Manali Kamdar, MD, of the University of Colorado, to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.
Jul 20, 2023 • 12min
S9 Ep12: Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer
Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.
Jul 17, 2023 • 14min
S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.
Jul 13, 2023 • 32min
S9 Ep10: Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management
Dr Lunning sits down with Jeremy Abramson, MD, of Massachusetts General Hospital, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.
Jul 10, 2023 • 14min
S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.
Jul 6, 2023 • 11min
S9 Ep8: King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer
Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer, findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease, and how the presence or absence of teratoma in the primary tumor should not preclude surgical resection in this population.
Jul 3, 2023 • 13min
S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.
